Trichomoniasis Overview

1. Introduction to Trichomoniasis

1.1. What is Trichomonas vaginalis?

Trichomoniasis is a very common sexually transmitted infection (STI), caused by a single-celled protozoan parasite named Trichomonas vaginalis. It is important to note that Trichomoniasis is caused by a parasite, not a virus. It is the most common non-viral STI globally and can be completely cured with medication. Although the disease is curable, the high global prevalence of Trichomoniasis highlights significant challenges in diagnosis, access to treatment, and disease control. Therefore, Trichomoniasis is sometimes considered a “neglected parasitic disease.”

1.2. Prevalence and Global Impact

Trichomoniasis is a global public health issue of significant scale. In the United States, an estimated 3.7 million people are infected. Globally, the World Health Organization (WHO) estimated approximately 156 million new T. vaginalis infections among people aged 15–49 in 2020, including 73.7 million cases in women and 82.6 million in men. About one-third of these new infections are concentrated in the WHO African region. Notably, the global incidence of T. vaginalis is higher than the sum of Chlamydia trachomatis, Neisseria gonorrhoeae, and syphilis combined.

Disease prevalence shows significant differences among population groups. Infection is more common in women than in men, and older women have a higher risk than younger women. In the United States, the disease is also more common in Black women. These epidemiological patterns are not random; they are linked to factors such as older age, lower education levels, lower socioeconomic status, and multiple sexual partners. Studies also indicate that structural racism has contributed to maintaining this significant disparity in the Black community. Socioeconomic factors and systemic inequalities play a crucial role in determining who gets infected and who is diagnosed and treated. Therefore, prevention and control efforts must be culturally sensitive, address health equity, and focus resources on affected or higher-risk communities and individuals, rather than solely on individual sexual behavior.

1.3. Transmission Methods and Non-Sexual Routes

The parasite Trichomonas vaginalis spreads from an infected person to an uninfected person during sexual intercourse. It is primarily transmitted through genital contact, including vaginal, oral, or anal sex. The most common transmissions are from penis to vagina, vagina to penis, or vagina to vagina. Additionally, it can also spread through skin-to-skin contact in the genital area without ejaculation. Sharing sex toys without proper cleaning or not using a condom can also transmit the parasite.

It is important to understand these transmission routes for effective prevention measures and to dispel common myths. Trichomoniasis is not spread through non-sexual contact, such as sharing food or drinks, kissing, or holding hands. Poor personal hygiene is also not a cause of Trichomoniasis, as it is a parasitic sexually transmitted disease. Although there are some rare reports suggesting potential transmission from towels, toilet seats, or swimming pools, in most cases, it is a sexually transmitted disease. Emphasizing sexual transmission while dispelling hygiene myths is critical for delivering effective public health messages. This helps shift the focus from shame or blame to understanding the actual routes of transmission, encouraging testing and treatment without stigma.

1.4. High-Risk Populations

Anyone who is sexually active can contract Trichomoniasis. However, some groups have a significantly higher risk. The disease is more common in women than in men, and older women have a higher risk than younger women. In the United States, Black women also have a higher prevalence. Key risk factors that increase the likelihood of infection include: not using a condom during sexual intercourse, having multiple sexual partners, a history of other STIs, having a new partner or contact with a confirmed infected partner, intravenous drug abuse, and not using any form of barrier contraception.

Identifying these specific high-risk groups is crucial for developing tailored public health interventions that go beyond general awareness. For example, women living with HIV are recommended for routine screening for T. vaginalis. Additionally, studies have shown that sex workers are a group with a very high prevalence, at 12.16% in one specific study. Public health campaigns and clinical guidelines should prioritize these groups with targeted screening, education, and service access, as a “one-size-fits-all” strategy will not be sufficient for effective Trichomoniasis control.

2. Signs and Symptoms of Trichomonas Infection

2.1. Symptoms in Women

When a Trichomonas infection causes symptoms, they can range from mild irritation to severe inflammation. Symptoms can begin 5 to 28 days after infection, or much later, and may appear and disappear. Common symptoms in women include:

• Abnormal Vaginal Discharge: Often thin or frothy, may be clear, white, yellow, or greenish, accompanied by an abnormal foul odor, often described as a “fishy smell.” Vaginal discharge is the main symptom women may experience, and in some cases, it may contain pus, along with vaginal redness and pain.
• Genital Irritation: Itching, burning, redness, or pain in the genital area, including the vulva and vagina.
• Discomfort during urination and sexual intercourse: A burning sensation or pain during urination (dysuria) and during sexual intercourse (dyspareunia).
• Lower Abdominal Pain: Some women may feel pain in the lower abdomen.
• “Strawberry Cervix”: A characteristic but rare clinical sign is a “strawberry” shaped cervix (colpitis macularis), with tiny red spots on the surface. This sign only appears in about 2-5% of cases.

2.2. Symptoms in Men

Unlike women, most men infected with Trichomoniasis do not have any symptoms. This is an important factor contributing to the spread of the disease. When symptoms do occur, they may include:

• Penile Irritation: Itching or irritation inside the penis.
• Burning sensation during urination or ejaculation: A burning sensation after urination or ejaculation.
• Penile Discharge: Discharge may be clear, pus-like, or frothy.
• Urethritis: Some men may experience urethral inflammation or urethral discharge.
• Less common symptoms: Testicular pain, frequent urination, or cloudy urine. In some cases, Trichomoniasis can cause urethritis, epididymitis, or prostatitis.

2.3. Asymptomatic Status and the Importance of Testing

One of the most challenging characteristics of Trichomoniasis is the high rate of asymptomatic cases. About 70% of infected individuals have no obvious signs or symptoms. This means many people are unaware they are infected and unintentionally transmit the parasite to others. Because symptoms are often vague or absent, Trichomoniasis cannot be diagnosed based on clinical signs alone. The absence of symptoms also allows the infection to persist for months or even years if left untreated. The high rate of asymptomatic infection is the main cause driving continuous transmission and making disease control difficult. This creates a vicious cycle where people unintentionally spread the infection, hindering effective public health control if only relying on symptom-based diagnosis. Therefore, accurate and timely diagnosis requires laboratory testing, especially for high-risk groups, even in the absence of symptoms. Thus, a proactive screening strategy and comprehensive partner treatment are extremely important to break the chain of transmission.

3. Consequences and Complications of Trichomonas Infection

Untreated Trichomoniasis can lead to numerous severe consequences and complications, affecting reproductive health, pregnancy, and increasing the risk of contracting other sexually transmitted infections.

3.1. Impact on Reproductive Health: Vaginitis, Cervicitis, Pelvic Inflammatory Disease (PID), and Infertility

In women, T. vaginalis is a common cause of vaginal discharge and is associated with an increased risk of developing Pelvic Inflammatory Disease (PID). PID is a serious inflammatory condition affecting the uterus, fallopian tubes, and ovaries, which can lead to infertility, increased risk of ectopic pregnancy, and chronic pelvic pain. Trichomoniasis can also cause vaginitis, cervicitis, and urethritis in women. Vaginitis is the most common clinical manifestation in symptomatic women. Additionally, T. vaginalis infection is also linked to infertility in women. Proposed mechanisms include the activation of the host’s immune system, leading to damage and inflammation of uterine and fallopian tube epithelial cells, as well as direct damage to oocytes and interference with ovulation. In men, T. vaginalis infection is also associated with infertility, potentially by impairing sperm motility through binding to sperm glycoproteins, causing phagocytosis and/or hindering the lateral movement of sperm, as well as direct damage and destruction of sperm cells.

3.2. Impact on Pregnancy and Newborns

Trichomoniasis infection during pregnancy is a serious concern as it is associated with adverse pregnancy outcomes. Pregnant women with Trichomoniasis are more likely to have preterm birth (delivering too early) and low birth weight babies (under 2.5 kg). It is also associated with premature rupture of membranes. Although rare, the infection can be transmitted to the baby as it passes through the birth canal, leading to vaginal and respiratory infections in the newborn. The link between Trichomoniasis and adverse pregnancy outcomes like preterm birth and low birth weight emphasizes the need for screening and treatment in pregnant women. Timely diagnosis and treatment are crucial during pregnancy. Metronidazole, the primary treatment drug, is considered safe for pregnant women. However, a notable point is that current guidelines do not recommend routine screening for asymptomatic pregnant women. This indicates a potential gap in public health policy or clinical practice, where the known risks of infection during pregnancy may not be adequately addressed by universal screening. Some experts have suggested that Trichomoniasis should be a reportable condition for pregnant women screening due to these adverse pregnancy outcomes. Healthcare providers should consider individual risk factors for pregnant patients to ensure timely diagnosis and treatment.

3.3. Link with HIV and other Sexually Transmitted Infections

Trichomoniasis infection can significantly increase the risk of contracting or transmitting other sexually transmitted infections. This parasite causes genital inflammation, creating a more favorable environment for HIV infection or transmitting the HIV virus to a partner. Increasing evidence shows that Trichomoniasis enhances HIV transmission. Conversely, people living with HIV may also have a higher risk of T. vaginalis infection. The inflammation caused by T. vaginalis acts as a biological cofactor, significantly increasing the risk of HIV acquisition and transmission. This means the infection is not just a nuisance but creates a biologically conducive environment for the spread of a much more severe STI like HIV. Therefore, treating and preventing Trichomoniasis can be a crucial strategy in the broader fight against HIV/AIDS, especially in areas with high prevalence or in key population groups. Additionally, Trichomoniasis is strongly associated with the presence of other STIs, including Chlamydia trachomatis, Neisseria gonorrhoeae, Treponella pallidum (syphilis), human papillomavirus (HPV), and herpes simplex virus (HSV) types 1 and 2.

3.4. Potential Link with Cancer (Cervical and Prostate)

Studies have indicated a potential link between T. vaginalis infection and the risk of certain cancers. T. vaginalis infection is associated with a higher risk of developing prostate or cervical cancer. For cervical cancer, individuals infected with T. vaginalis have a higher risk, especially when co-infected with human papillomavirus (HPV). This association is supported by meta-analyses. Proposed reasons include a higher rate of co-infection with high-risk HPV types. This suggests a possible synergistic effect where T. vaginalis creates a favorable environment for HPV infection or the progression of precancerous lesions to cancer. This finding reinforces the importance of comprehensive STI screening and management, including HPV vaccination and cervical cancer screening, as part of a holistic approach to sexual health. For men, T. vaginalis infection is also associated with prostate cancer, although studies are inconclusive and remain controversial. Some studies suggest that this parasite may cause proliferation of prostatic epithelial cells and chronic inflammation. The link with cervical and prostate cancer, especially the synergistic effect with HPV for cervical cancer, suggests a more complex and serious long-term impact than previously understood for Trichomoniasis.

4. Diagnosis of Trichomoniasis

4.1. When is Trichomonas Testing Needed?

The diagnosis of Trichomoniasis cannot rely solely on clinical symptoms, so laboratory testing is essential to confirm the infection. Testing is used to diagnose infection in symptomatic individuals. Even in the absence of clear symptoms, testing may be recommended for high-risk women, such as those who have unprotected sexual intercourse, have multiple sexual partners, or have a history of other STIs. Retesting is also recommended after completing treatment to ensure the infection has been completely eliminated and there is no reinfection. When a patient presents for examination, the healthcare provider will discuss their medical and sexual history and conduct a genital examination to look for suggestive signs. However, it should be noted that routine gynecological or urological examination often does not include identifying Trichomoniasis.

4.2. Modern Testing Methods and Accuracy

There are several different testing methods for diagnosing Trichomonas vaginalis, each with its own advantages and disadvantages in terms of sensitivity, specificity, time to results, and cost.

• Wet Mount Microscopy (Soi tươi dịch tiết): This method has traditionally been preferred for women because it is inexpensive and can be performed on-site in the clinic. However, it has low sensitivity (44%–68%) compared to culture. The sensitivity of the wet mount test decreases rapidly, dropping to only about 20% within 1 hour after sample collection. This method is not suitable for men due to very low sensitivity.
• Nucleic Acid Amplification Tests (NAATs): NAATs have very high sensitivity (95–100%) and high specificity (95–100%). They are considered the gold standard in some settings for the diagnosis of T. vaginalis. NAATs are approved by the U.S. Food and Drug Administration (FDA) for use in symptomatic or asymptomatic women using vaginal swab samples (collected by a clinician or self-collected), cervical swabs, urine samples, and liquid-based cervical cytology samples (liquid Pap smear). Some NAATs are also FDA-approved for male urine samples. The shift from wet mount to NAATs as the “gold standard” indicates a major improvement in diagnostic accuracy, which plays a critical role in identifying asymptomatic cases and improving public health control.
• Rapid Antigen Tests (Các xét nghiệm nhanh): Examples include the OSOM Trichomonas Rapid Test, which can be performed on-site and provides results in 10-15 minutes. These tests have a sensitivity of 82%–95% and a specificity of 97%–100%. However, they are mainly for women, and the OSOM test is not recommended for men due to low sensitivity (38%).
• Culture (Nuôi cấy): Previously, culture was considered the gold standard for diagnosing T. vaginalis. This method has a sensitivity of 75%–96% but results often take 3-7 days. For women, vaginal discharge samples are preferred because urine culture is less sensitive. For men, a urethral swab, centrifuged urine sediment, or semen sample is needed.
• Pap Smears (Phết tế bào cổ tử cung): Pap smears are not suitable for routine Trichomoniasis screening or diagnosis due to poor sensitivity. However, if Pap smear results suggest a possible asymptomatic infection, additional tests (wet mount, NAAT, culture, or rapid test) should be performed to confirm the diagnosis.

4.3. Specimen Collection Procedures for Men and Women

The specimen collection procedure for Trichomonas vaginalis testing varies depending on the gender and the type of test used:

• For Women: Samples can be collected from vaginal discharge (by a clinician or self-collected with a swab), cervical swabs, or urine samples.
• For Men: Samples can be collected from the urethra (with a swab), urine (first-void urine sample), or semen.
• Note for Urine Sample Collection: To ensure accuracy, patients should not urinate for at least one hour before sample collection. Approximately 20-30 mL of first-void urine (the first part of the urine stream) should be provided in a clean container.

Table 1: Comparison of Diagnostic Methods for Trichomonas vaginalis

5. Treatment of Trichomonas

5.1. Main Treatment Medications and Mechanism of Action

Trichomoniasis is a disease that can be effectively treated and cured with medication. The main class of antibiotics known to be effective against T. vaginalis is nitroimidazole. The most common drugs in this group are metronidazole and tinidazole. Secnidazole is also another treatment option. These drugs work by interfering with the parasite’s DNA synthesis process, leading to their destruction.

5.2. Recommended Treatment Regimens according to CDC and WHO Guidelines

Treatment guidelines from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend specific regimens for men and women:

• For Women: The recommended regimen is Metronidazole 500 mg orally twice daily for 7 days.
• For Men: The recommended regimen is Metronidazole 2 g orally as a single dose.
• Alternative Regimen (for both men and women): Tinidazole 2 g orally as a single dose. Tinidazole is often more expensive but can achieve higher concentrations in the serum and urogenital tract, has a longer half-life than metronidazole, and fewer gastrointestinal side effects.

A critical note is the avoidance of alcohol during treatment with nitroimidazoles. Traditionally, alcohol abstinence has been recommended for 24 hours after metronidazole and 72 hours after tinidazole to avoid a disulfiram-like reaction. However, recent CDC guidelines suggest that limited alcohol consumption (no more than one drink per day) may be acceptable when taking metronidazole, as direct inhibition of acetaldehyde dehydrogenase is not observed.

5.3. Treatment for Pregnant and Breastfeeding Women

Treatment of Trichomoniasis during pregnancy is very important due to potential risks to the fetus. Metronidazole is considered safe for pregnant women. Pregnant patients can receive a metronidazole regimen similar to non-pregnant patients (Metronidazole 500 mg twice daily for 7 days). Although some clinicians may prefer to delay treatment until the second trimester, timely treatment is necessary once the diagnosis is confirmed. For breastfeeding women, metronidazole passes into breast milk and may affect the taste. Manufacturers recommend avoiding high doses or interrupting breastfeeding for 12-24 hours after a single dose to reduce infant exposure. Tinidazole and Secnidazole are generally not recommended for pregnant women due to a lack of adequate safety studies. Tinidazole is classified as a Category C drug in pregnancy, and the manufacturer contraindicates its use in the first trimester.

5.4. Partner Management to Prevent Reinfection

To achieve long-term treatment effectiveness and prevent reinfection, partner management is an extremely critical factor. About 1 in 5 people become reinfected within 3 months after treatment. This usually happens if sexual intercourse occurs without a condom with an untreated partner. Therefore, to avoid reinfection, all sexual partners must be treated at the same time as the patient. Patients should abstain from sexual activity until both the patient and all partners have completed treatment and all symptoms have disappeared, usually about 7-10 days after finishing the medication course. The high rate of reinfection despite the possibility of a cure highlights the challenges in partner notification and adherence to treatment and abstinence guidelines. This emphasizes that public health efforts need to improve strategies for partner services (notification, testing, treatment), and patient counseling must strongly emphasize the importance of partner treatment and temporary abstinence to achieve a lasting cure and prevent community spread.

5.5. Managing Cases of Reinfection or Drug Resistance

In some cases, Trichomoniasis can recur or become drug-resistant, making treatment difficult. Recurrent cases may be due to non-adherence to treatment (not taking the full dose or for the full duration), reinfection from an untreated partner, or the parasite having developed resistance to metronidazole. Metronidazole resistance occurs in 4-10% of vaginal Trichomoniasis cases. If symptoms still persist after the initial therapy, these possibilities should be considered. For the first treatment failure, retreatment with metronidazole 500mg orally twice daily for 7 days is recommended. If this second treatment fails, metronidazole 2g orally once daily for 3-5 days may be used. For persistent treatment failure, expert consultation and consideration of T. vaginalis metronidazole susceptibility testing are required. The CDC provides recommendations for managing recurrent/persistent Trichomoniasis and performing susceptibility testing for refractory cases. Tinidazole can be effective against some metronidazole-resistant strains. Other alternative regimens tested for resistant cases include high-dose metronidazole (2g daily for 7 days) or tinidazole (2g daily for 14 days along with 500mg vaginal tinidazole twice daily).

6. Prevention of Trichomonas Infection

6.1. Effective Prevention Measures for Both Men and Women

The only way to completely avoid all STIs, including Trichomoniasis, is to abstain from vaginal, anal, or oral sex. However, if sexually active, the risk of infection can be significantly reduced by adopting the following measures:

• Monogamy: Maintain a long-term, mutually monogamous relationship with a partner who has been tested and is negative for STIs, and only have sexual intercourse with that one partner.
• Correct Condom Use: Use a latex condom correctly every time you have sexual intercourse. It is crucial to put the condom on before the penis touches the vagina, mouth, or anus. However, it should be noted that the parasite T. vaginalis can infect skin areas not covered by the condom, so condoms may not provide complete protection in all cases. Acknowledging the incomplete protection of condoms against Trichomoniasis due to skin-to-skin contact outside the covered areas is an important nuance for informed prevention. This suggests that Trichomoniasis prevention strategies should emphasize a multifaceted approach, including monogamy, partner testing, and open communication, in addition to condom use.
• Open Communication: Discuss potential STI risks with new partners before sexual intercourse.
• Limit the Number of Partners: Reducing the number of sexual partners also helps reduce the risk of exposure.
• Avoid Vaginal Douching: Do not douche the vagina, as this can eliminate the natural beneficial bacteria in the vagina, increasing the risk of infection.
• Avoid Substance Abuse: Avoid abusing alcohol or illegal drugs, as they can impair judgment and lead to risky sexual behavior.
• Understand Ineffective Measures: Washing genitals, urinating, or douching after sexual intercourse will not prevent any STI.

6.2. Regular Screening and Sexual Health Counseling for High-Risk Groups

Regular screening and sexual health counseling play a vital role in preventing and controlling Trichomoniasis, especially for high-risk groups. Routine testing for Trichomoniasis and other STIs is recommended. Open and honest communication with partners about sexual history and potential risks is an essential part of effective prevention. Prevention counseling should be offered to all sexually active adolescents and high-risk adults. While screening is not generally recommended for asymptomatic women, it can be considered in areas with high prevalence or for women at high risk, such as those with multiple partners, sex in exchange for money, use of illegal drugs, or a history of STIs. The CDC specifically recommends routine screening for T. vaginalis for asymptomatic people with HIV infection.

7. Post-Treatment Follow-up and Risk of Reinfection

7.1. Follow-up Schedule and Retesting

After completing treatment for Trichomoniasis, follow-up is necessary to ensure the infection has been completely eliminated and to prevent reinfection. For women with a positive test result for Trichomoniasis, retesting is recommended 3 months after treatment. The primary purpose of this retesting is to detect any cases of reinfection. For men, retesting is generally not necessary unless symptoms return. If any symptoms of Trichomoniasis reappear after treatment, both men and women should seek medical care again immediately for evaluation and timely treatment.

7.2. Factors that Increase the Risk of Reinfection

Reinfection with Trichomoniasis is a common problem, with about 1 in 5 people becoming reinfected within 3 months after the initial treatment. This can happen if sexual intercourse occurs without a condom with a partner who is still infected with Trichomoniasis. Reinfection is particularly common in sexually active people. Key factors that increase the risk of reinfection include: inadequate treatment (not completing the full course or not taking the correct dose), reinfection from an untreated partner, or in rare cases, the parasite having developed resistance to metronidazole. The high rate of reinfection despite the possibility of a cure indicates challenges in partner notification and adherence to treatment and abstinence guidelines. Simultaneous partner management and abstinence from sexual intercourse until both parties have completed treatment and are symptom-free is crucial to break the chain of transmission and achieve long-term treatment effectiveness.

8. Co-infection and Differential Diagnosis

8.1. Co-infection with other STI Agents

Co-infection with other urogenital pathogens is very common in individuals with Trichomoniasis. A Trichomoniasis diagnosis should trigger a broader STI screening, as the presence of one STI is an indicator of an increased risk for other diseases. Commonly co-infecting pathogens include Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum (syphilis), human papillomavirus (HPV), and herpes simplex virus (HSV) types 1 and 2. Specifically, women with bacterial vaginosis (BV) are highly likely to be co-infected with T. vaginalis (co-infection rate of 60-80%) and Candida spp. (20-30%). Due to the high co-infection rate, if T. vaginalis or abnormal vaginal discharge is present, testing for other STIs like HIV and syphilis is recommended. All women with BV should also be tested for HIV and other STIs. The high rate of co-infection requires a “syndromic approach” or comprehensive STI panel testing when Trichomoniasis is suspected or diagnosed. Healthcare providers should adopt a holistic screening approach, especially in high-risk populations, to effectively manage STIs and prevent further transmission and complications.

8.2. Which Agents are Trichomoniasis Symptoms Easily Confused With?

Sexually transmitted diseases (STIs) such as Chlamydia, Gonorrhea, and Trichomoniasis often have similar symptoms like abnormal discharge, painful urination, or itching, making differential diagnosis difficult if relying only on symptoms. This emphasizes the need for professional medical diagnosis through testing. Below is a comparison of Trichomoniasis symptoms with some other common intimate area conditions: (Note: The detailed comparison table was provided in a previous response.)

Table 2: Differentiating Symptoms between Trichomoniasis and Common Intimate Area Conditions

9. Conclusion

Trichomoniasis, caused by the parasite Trichomonas vaginalis, is the most common non-viral sexually transmitted infection globally. Although curable, the high prevalence and large number of asymptomatic cases have created significant challenges in controlling the disease. The high asymptomatic rate (about 70%) means many people are unaware they are infected and unintentionally transmit the disease, making symptom-based diagnosis unreliable and hindering prevention efforts. The disease can cause many serious consequences for reproductive health in both men and women, including vaginitis, cervicitis, pelvic inflammatory disease, and infertility. Notably, for pregnant women, Trichomoniasis is associated with adverse pregnancy outcomes like preterm birth, low birth weight, and premature rupture of membranes. Furthermore, Trichomoniasis infection significantly increases the risk of acquiring and transmitting HIV by causing genital inflammation, creating a favorable condition for the HIV virus to enter. The potential link with cervical cancer (especially when co-infected with HPV) and prostate cancer is also a critical aspect of this disease. Accurate diagnosis of Trichomoniasis requires laboratory testing, with Nucleic Acid Amplification Tests (NAATs) currently considered the gold standard due to their high sensitivity and specificity. Treatment with metronidazole or tinidazole is effective, but adherence to the treatment regimen and simultaneous treatment of all partners is necessary to prevent reinfection, a common problem due to untreated partners. For prevention, safe sexual practices such as maintaining monogamy, correct condom use, and limiting the number of partners are crucial. However, it should be noted that condoms may not provide complete protection due to the potential for transmission through skin-to-skin contact in uncovered areas. Regular screening, especially in high-risk groups such as women with HIV or those with multiple partners, along with open sexual health counseling, are essential strategies for controlling the spread of the disease. The high rate of co-infection with other STIs also emphasizes the need for comprehensive screening when Trichomoniasis is diagnosed. Overall, raising community awareness about Trichomoniasis, improving access to advanced diagnostic and treatment methods, along with implementing comprehensive prevention strategies and effective partner management, are crucial steps to reduce the burden of this common yet often neglected disease.

This article is written by Dr Đỗ Hữu Đạt. The doctor has many years of in-depth experience in reproductive and sexual health care.

Reference

[1]. Trichomoniasis – CDC Fact Sheet. – DPBH, https://dpbh.nv.gov/uploadedFiles/dpbh.nv.gov/content/Programs/STD/dta/Publications/Trichomoniasis.pdf 

[2]. Trichomoniasis – Symptoms & causes – Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/trichomoniasis/symptoms-causes/syc-20378609

[3]. Trichomoniasis – World Health Organization (WHO), https://www.who.int/news-room/fact-sheets/detail/trichomoniasis

[4]. Trichomoniasis: Causes, Symptoms, Testing & Treatment – Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/4696-trichomoniasis

[5]. Trichomoniasis: Symptoms, Causes, and Treatment, – WebMD, https://www.webmd.com/sexual-conditions/trichomoniasis

[6]. Trichomoniasis – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10713349/

[7]. About Trichomoniasis – CDC, https://www.cdc.gov/trichomoniasis/about/index.html

[8]. The Past, Present, and Future in the Diagnosis of a Neglected Sexually Transmitted Infection: Trichomoniasis – MDPI, https://www.mdpi.com/2076-0817/13/2/126

[9]. Brasil – Factors associated with Trichomonas <i>vaginalis … – SciELO, https://www.scielo.br/j/bjid/a/GGk5X4PZDMCHkMtb8zS4rvy/?lang=en

[10]. Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines – PMC – National Institutes of Health (NIH) |, https://pmc.ncbi.nlm.nih.gov/articles/PMC9006969/

[11]. 2018 European (IUSTI/WHO) International Union against sexually …, https://iusti.org/wp-content/uploads/2019/12/Vagdx2018.pdf

[12]. Trichomoniasis – StatPearls – NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK534826/

[13]. Vaginitis – Bacterial Vaginosis, Vulvovaginal Candidiasis, and Trichomoniasis | Choose the Right Test – ARUP Consult, https://arupconsult.com/content/vaginitis-bacterial-vaginosis-vulvovaginal-candidiasis-and-trichomoniasis

[14]. Trichomonas vaginalis infection-associated risk of cervical cancer: A …, https://www.researchgate.net/publication/325863559_Trichomonas_vaginalis_infection-associated_risk_of_cervical_cancer_A_meta-analysis

[15]. Trichomoniasis – STI Treatment Guidelines – CDC, https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm

[16]. Persistent Trichomoniasis in Pregnancy: A Case Report Calling for Further Research to Alternative Antibiotic Treatment – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12001296/.

[17]. Vaginal Microbiota of the Sexually Transmitted Infections Caused by Chlamydia trachomatis and Trichomonas vaginalis in Women with Vaginitis in Taiwan – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC8470505/

[18]. Trichomoniasis Test: MedlinePlus Medical Test, https://medlineplus.gov/lab-tests/trichomoniasis-test/

[19]. Advances in Laboratory Detection of Trichomonas vaginalis – APHL, https://www.aphl.org/aboutAPHL/publications/Documents/ID_2013August_Advances-in-Laboratory-Detection-of-Trichomonas-vaginalis.pdf

[20]. Update on Guidelines and Technology in the Diagnosis and Treatment of Trichomonas vaginalis, https://cdn.mdedge.com/files/s3fs-public/obg_reachmd_0416_0.pdf

[21]. Trichomoniasis Testing, https://www.testing.com/tests/trichomoniasis-testing/

[22]. Trichomonas vaginalis by NAAT – MU Health Care Laboratory Test Catalog, https://muhealth.testcatalog.org/show/Trich-by-NAAT

[23]. Bacterial Vaginosis – STI Treatment Guidelines – CDC, https://www.cdc.gov/std/treatment-guidelines/bv.htm

[24]. What is the recommended treatment for Trichomonas vaginalis? – Dr.Oracle AI, https://www.droracle.ai/articles/204000/treatment-guideline-for-trichomonas-vaginalis

[25]. Trichomoniasis – 2015 STD Treatment Guidelines, http://medbox.iiab.me/modules/en-cdc/www.cdc.gov/std/tg2015/trichomoniasis.htm

[26]. Updated CDC guidelines: Diagnosing and treating STIs – Contemporary OB/GYN, https://www.contemporaryobgyn.net/view/updated-cdc-guidelines-on-treating-sexually-transmitted-infections

[27]. Summary of CDC STI Treatment Guidelines, 2021, https://www.cdc.gov/std/treatment-guidelines/wall-chart.pdf

[28]. Trichomoniasis – Diagnosis & treatment – Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/trichomoniasis/diagnosis-treatment/drc-20378613

[29]. Parasites – Trichomonas vaginalis Susceptibility Testing – CDC, https://www.cdc.gov/parasites/resources/Trichomonas_vaginalis.html

[30]. Trichomoniasis – CDC stacks, https://stacks.cdc.gov/view/cdc/165381/cdc_165381_DS1.pdf

[31]. Sexually Transmitted Diseases Treatment Guidelines, 2015 – CDC, https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm

[32]. Retesting After Treatment to Detect Repeat Infections – CDC, https://www.cdc.gov/std/treatment-guidelines/clinical-retesting.htm

[33]. Chlamydia vs Gonorrhea vs Trichomoniasis | Call-On-Doc – CallonDoc, https://www.callondoc.com/en/blogs/chlamydia-vs-gonorrhea-vs-trichomoniasis

[34]. 188052: Trichomonas vaginalis, NAA – Labcorp, https://www.labcorp.com/tests/188052/trichomonas-vaginalis-naa

[35]. Yeast infection (vaginal) – Symptoms and causes – Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/yeast-infection/symptoms-causes/syc-20378999

[36]. CDC Updates Trichomoniasis Treatment Guidelines | Clinician.com, https://www.clinician.com/articles/149429-cdc-updates-trichomoniasis-treatment-guidelines